Hims & Hers Health/$HIMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hims & Hers Health
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Ticker
$HIMS
Sector
Primary listing
NYSE
Employees
1,637
Headquarters
Website
HIMS Metrics
BasicAdvanced
$12B
64.52
$0.79
2.09
-
Price and volume
Market cap
$12B
Beta
2.09
52-week high
$72.98
52-week low
$15.73
Average daily volume
30M
Financial strength
Current ratio
4.979
Quick ratio
4.205
Long term debt to equity
185.047
Total debt to equity
185.604
Interest coverage (TTM)
112.13%
Profitability
EBITDA (TTM)
160.154
Gross margin (TTM)
76.20%
Net profit margin (TTM)
9.62%
Operating margin (TTM)
6.50%
Effective tax rate (TTM)
-39.05%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
6.95%
Return on equity (TTM)
41.88%
Valuation
Price to earnings (TTM)
64.515
Price to revenue (TTM)
5.573
Price to book
20.42
Price to tangible book (TTM)
28.42
Price to free cash flow (TTM)
93.904
Free cash flow yield (TTM)
1.06%
Free cash flow per share (TTM)
0.542
Growth
Revenue change (TTM)
88.69%
Earnings per share change (TTM)
866.21%
3-year revenue growth (CAGR)
75.30%
3-year earnings per share growth (CAGR)
24.29%
What the Analysts think about HIMS
Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.
Bulls say / Bears say
Diversification into new specialties and diagnostics: CEO Andrew Dudum is targeting under-insured consumers by launching a diagnostics lab and expanding into low testosterone and menopause treatments, reducing reliance on GLP-1 compounding and broadening the platform’s addressable market. (Reuters)
Ambitious long-term growth target: Hims & Hers projects revenue of $6.5 billion by 2030, underscoring confidence in its scalable telehealth platform and the ability to expand beyond core weight-loss offerings. (Reuters)
Resilience amid regulatory headwinds: Following the FDA ban on compounded Wegovy, Hims & Hers achieved a 111% increase in Q1 2025 revenue and is exploring partnerships with Novo Nordisk while entering high-growth markets such as sleep, longevity, and hormone health to sustain momentum. (Reuters)
Execution risk highlighted by Q2 revenue miss: Second-quarter revenue of $544.8 million fell short of the $552 million consensus, triggering a 12% stock decline and signaling potential difficulty in meeting analyst expectations. (WSJ)
Regulatory threat to core product: The FDA’s resolution of the semaglutide shortage and ban on compounded versions effective May 22, 2025 undermines a key GLP-1 weight-loss revenue stream, creating significant uncertainty for future sales. (Reuters)
Legal and competitive risks: Analysts question the legitimacy of Hims & Hers’ personalized compounding dosages and warn of potential legal challenges from Novo Nordisk, which could lead to further partnership terminations and hinder the GLP-1 business model. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
HIMS Financial Performance
Revenues and expenses
HIMS Earnings Performance
Company profitability
HIMS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hims & Hers Health stock?
Hims & Hers Health (HIMS) has a market cap of $12B as of September 17, 2025.
What is the P/E ratio for Hims & Hers Health stock?
The price to earnings (P/E) ratio for Hims & Hers Health (HIMS) stock is 64.52 as of September 17, 2025.
Does Hims & Hers Health stock pay dividends?
No, Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Hims & Hers Health dividend payment date?
Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders.
What is the beta indicator for Hims & Hers Health?
Hims & Hers Health (HIMS) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.